Federal Register #USTR20260463

USTR Requests Public Comments on Germany's Pharmaceutical Pricing Policies (Section 301 Investigation)

This opportunity concerns a U.S. government investigation into Germany's pharmaceutical pricing policies: - Government buyer: - Office of the United States Trade Representative (USTR) - Purpose: - Section 301 investigation into Germany's underpayment for innovative pharmaceutical products - Focus on pricing policies that may suppress prices below fair market value - No OEMs or vendors are named in the notice - No products or services are being requested for procurement - The USTR is seeking public comments and testimony regarding: - Germany's acts, policies, and practices related to pharmaceutical pricing - The impact on U.S. commerce and pharmaceutical R&D costs - Potential actions under Section 301 - No purchase quantities, part numbers, or specific products are listed - The Section 301 Committee will hold a public hearing and invites written comments from interested parties

Description

The United States Trade Representative (USTR) has initiated a Section 301 investigation pursuant to the Trade Act of 1974 regarding Germany's persistent underpayment for innovative pharmaceutical products. The investigation focuses on Germany's pricing policies that suppress pharmaceutical prices below fair market value, causing the U.S. to bear a disproportionate share of global pharmaceutical R&D costs. The inter-agency Section 301 Committee is holding a public hearing and seeking public comments on this matter. The hearing is scheduled for September 22, 2026, with written comments due by August 10, 2026.

View original listing